Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 27 August 2008, doi:10.1136/bmj.a1304
Cite this as: BMJ 2008;337:a1304
David Wald, consultant cardiologist and senior lecturer
1 Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine, London EC1M 6BQ
d.s.wald@qmul.ac.uk
| The first 150 words of the full text of this article appear below. |
The recommendations from the National Institute for Health and Clinical Excellence (NICE) on the management of familial hypercholesterolaemia give guidance in three general areas: diagnosis, treatment, and screening to identify new cases.1 The guidelines are immediately applicable to diagnosis and treatment, but the way forward on screening will need a new approach.
The guidelines propose cascade testing, a term used to describe searching for affected relatives of an inherited disorder once an affected person is known and repeating this process every time another affected individual is found. This is appropriate in general medical practice as 1 in 2 first degree relatives of someone with familial hypercholesterolaemia will also have the condition. The diagnosis of an index case is initially made clinically, and a gene mutation causing familial hypercholesterolaemia is found in up to about 80% of cases, depending on which test is used.1
The guidelines recommend that cascade testing include
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses